Friday, July 10, 2026

pharma · Rheumatoid Arthritis · Multiple Myeloma

Centocor

Centocor is a pharma organization headquartered in EU. Primary therapeutic focus areas include Rheumatoid Arthritis, Multiple Myeloma. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s)

Malvern, USA HQ
1979 Founded
568 Employees
EMA registrant Type
Company details
Status
Public
HQ
Malvern, USA
Founded
1979
Employees
568
Programs
2
Drugs
4
Patents
1

Quick answer

Centocor is a pharma organization headquartered in EU. Primary therapeutic focus areas include Rheumatoid Arthritis, Multiple Myeloma. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (2).

Company snapshot

Subsidiary of Johnson & Johnson, Centocor is a biotechnology company that was founded in Philadelphia in 1979 with an initial goal of developing new diagnostic assays using monoclonal antibody technology. In 1982 Centocor developed their first product approved by the U.S. Food and Drug Administration (FDA) — a diagnostic test used to detect the rabies virus, and in that same year transitioned into

  • 2 active pipeline program(s) linked via ClinicalTrials.gov.
  • 1 US patent(s) indexed to this assignee profile.
  • 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Centocor. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for Centocor.

1 active signal

13 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 2 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Centocor.

  1. Clinical update

    Placebo, Velcade and dexamethasone — Phase 3

  2. Clinical update

    Placebo injections — Phase 3

  3. Patent grant

    MODÈLE DE MARQUEUR DE MATRICE ET PROCÉDÉS POUR ÉVALUER ET TRAITER L'ARTHRITE ET DES TROUBLES ASSOCIÉS

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Centocor?

    Centocor is a pharma organization headquartered in EU. Primary therapeutic focus areas include Rheumatoid Arthritis, Multiple Myeloma. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, an

  • Is Centocor publicly traded?

    Centocor appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Centocor develop or market?

    We link 4 drug profile(s) where Centocor is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/centocor-b-v#company-drugs.

  • What are the latest developments for Centocor?

    In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Centocor focus on?

    Centocor focuses on Rheumatoid Arthritis, Multiple Myeloma based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
3
Immunology
2